Rick Bangs
Bladder Cancer Advocacy Network · 85 works · 3,291 citations · h-index 20
Top works
- Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
- Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
- Bladder Cancer, Version 3.2024
- NCCN Guidelines Insights: Bladder Cancer, Version 5.2018
- Patient‐centered prioritization of bladder cancer research
- NCCN Guidelines Insights: Bladder Cancer, Version 2.2016
- Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer
- A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)
- A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies
- Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605
- Addressing Skyrocketing Cancer Drug Prices Comes With Tradeoffs
- Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.
- Suggestions for Regulatory Agency Approval of Second-Line Systemic Therapy for Metastatic Transitional Cell Carcinoma
- End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer
- Interventions addressing health-related social needs among patients with cancer
- Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop
- Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
- Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).